Please select the option that best describes you:
Topics:
Lung Cancer • Melanoma/Skin Cancer • Thoracic Malignancies • Medical Oncology • Immunotherapy
Would you use immune checkpoint inhibitors in patients with well-compensated liver cirrhosis?
Does the risk of severe inflammation of the liver lead you to choose other therapies in in this population? What about in patients with mild liver disease, such as early NASH cirrhosis?
Answer from: Medical Oncologist at Academic Institution
There are essentially no good data describing the safety and efficacy of immune checkpoint inhibitors in patients with compromised organ function. The issue is complex, in that altered liver function will change protein binding of the drugs, potentially alter catabolism etc. Autoimmun...
Sign in or Register to read more